Cancer Treatment An Update

Front Matter....Pages I-XXI
Front Matter....Pages 1-1
The pathogenesis of human cancer metastasis....Pages 3-6
The role of molecular genetics in medical oncology....Pages 7-9
Cell line-based screening for new anticancer drugs....Pages 10-16
Anti-EGF receptor monoclonal antibodies as potential anti-cancer therapy....Pages 17-18
Clinical relevance of drug resistance: Where do we stand now and where are we going to ?....Pages 19-23
Mobilization, purification and ex vivo expansion of human peripheral blood progenitor cells....Pages 24-28
Fluoropyrimidine cancer chronotherapy....Pages 29-39
Chemo-immunotherapy of metastatic malignant melanoma The Salpetriere Hospital (SOMPS) experience....Pages 40-46
Concomitant chemoradiotherapy for solid tumors....Pages 47-49
Current status of therapy for small cell carcinoma of the lung....Pages 50-54
Systemic treatment of bladder cancer....Pages 55-61
Metastatic breast cancer: current management options and future directions....Pages 62-65
Present and future prospects for the chemotherapy of gliomas....Pages 66-69
Neo-Adjuvant chemotherapy in breast cancer Study of 477 evaluable patients with primary breast cancers treated between 1980 and 1992....Pages 70-78
Osteogenic sarcoma: a 15-year experience in treating 287 patients with preoperative chemotherapy....Pages 79-84
Cell cycle regulation and the chemosensitivity of cancer cells....Pages 85-89
Reversal of multidrug resistance in hematologic malignancies with chemosensitizers: laboratory and clinical studies....Pages 90-97
Practical approach to bladder cancer....Pages 98-102
Front Matter....Pages 103-103
Primary chemotherapy for breast cancer: response to preoperative chemotherapy as prognostic factor....Pages 105-109
Breast cancer, cytoprognostic grades and proliferative activity (DNA ploidy, S phase)....Pages 110-113
Front Matter....Pages 103-103
Primary chemotherapy in the individualized non-mutilating treatment of breast cancer....Pages 114-119
Neo-Adjuvant chemotherapy in 100 patients with locally advanced carcinoma of the breast....Pages 120-122
Surgical aspects of the conservative treatment of large size breast cancer after primary chemotherapy....Pages 123-126
Efficacy of a chemotherapy regimen combining Vinorelbine, Epirubicine and Methotrexate (VEM) in locally advanced and metastatic breast cancer....Pages 127-130
Recurrent breast carcinoma after conservative treatment: MRI features and pathologic correlation....Pages 131-134
Intensive chemotherapy for inflammatory breast cancer: how much clinical value ?....Pages 135-145
A Phase II study of 2-weekly high-dose Epirubicin with r-met-hu G-CSF in advanced breast cancer....Pages 146-149
Cyclophosphamide, Novantrone, Fluorouracil (CNF) + G-CSF Neo-Adjuvant chemotherapy in operable breast cancer....Pages 150-154
Adjuvant chemohormonal therapy with Cyclophosphamide, Doxorubicin and 5-Fluorouracil (CAF) with or without medroxyprogesterone acetate (MPA) in node-positive breast cancer patients....Pages 155-159
Follow-up results of an ECOG study of adjuvant therapy in post-menopausal women with breast cancer....Pages 160-162
Long-term efficacy and late sequelae of Doxorubicin-containing adjuvant therapy for breast cancer: MD Anderson Cancer Center studies....Pages 163-166
Taxol in metastatic breast cancer: the MD Anderson Cancer Center experience....Pages 167-171
Taxol plus recombinant human granulocyte colony stimulating factor as salvage chemotherapy for metastatic breast cancer....Pages 172-175
Front Matter....Pages 177-177
A model for chemosentivity testing using in vitro MTT assay on a human squamous carcinoma tongue cell line....Pages 179-184
Head and neck cancer treatment: present status and future direction....Pages 185-190
Chemotherapy (CT) followed by radiotherapy (RT) vs. RT alone in patients with resected and negative margins squamous cell carcinoma of the head and neck: Phase III Intergroup Study....Pages 191-195
Neo-adjuvant infusion Cisplatin, 5-FU and high-dose leucovorin for squamous cell carcinoma of the head and neck (SCCHN): high rates of complete response (CR) and definitive radiotherapy as primary site management....Pages 196-200
Primary (Neo-Adjuvant) combined modality therapy in the management of locally advanced squamous cell carcinoma of the head and neck....Pages 201-206
A Phase II trial of induction Cisplatin, 5-FU, Leucovorin, and Interferon α -2B (PFL- α ) followed by concurrent Hydroxyurea, 5-FU and radiation for Stage IV squamous cell cancers of the head and neck (HNC)....Pages 207-210
Induction chemotherapy with Cisplatin (P), 5-Fluorouracil (FU) and Folinic Acid (FA) in locally advanced head and neck cancer....Pages 211-213
Front Matter....Pages 177-177
A randomized study of CDDP and 5-FU as Neo-Adjuvant chemotherapy in head and neck cancer: an interim analysis....Pages 214-218
Concomitant chemoradiotherapy in locally advanced head and neck cancers: a prospective study of 68 patients....Pages 219-224
Epidermal growth factor receptor in upper aerodigestive tract cancer....Pages 225-233
Concomitant α -Interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck....Pages 234-236
Thymidylate synthase activity and Folate levels in head and neck squamous cell carcinomas....Pages 237-242
Long term nephrotoxicity of Cisplatinum (CDDP) in man....Pages 243-247
Prognostic factors in head and neck cancer patients included in a program of Neo-Adjuvant chemotherapy and radical radiotherapy....Pages 248-250
Induction chemotherapy for larynx preservation in laryngeal and hypopharyngeal cancers....Pages 251-256
A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck....Pages 257-259
Concomitant radiotherapy and Cisplatin in head and neck cancer: a pilot study....Pages 260-262
Ifosfamide/Mesna plus Carboplatin as Neo-Adjuvant therapy for stage I–III head and neck cancer. Preliminary report....Pages 263-266
Role of Ifosfamide, Cisplatinum (IC) combination in the metastatic neck nodes....Pages 267-273
Clinical pharmacokinetics of Pure 1 Folinic Acid and Fluorouracil during a phase I–II trial of Fluorouracil biomodulation in head and neck cancer patients. Preliminary data....Pages 274-279
Long-term follow-up of the patients with recurrent or advanced head and neck cancer who received chemotherapy for palliation....Pages 280-282
Intensified concomitant chemoradiotherapy for poor prognosis head and neck cancer....Pages 283-287
Response to chemotherapy of ulcerative lymphoma of the midface....Pages 288-290
A multicentric study of the GETTEC (Groupe d’Études des Tumeurs de la Tête et du Cou) about 408 clinically complete responders after Neo-Adjuvant chemotherapy for head and neck carcinomas....Pages 291-294
Chemotherapy of undifferentiated thyroid cancer (UCT) and sarcoma of the thyroid gland (ST)....Pages 295-297
Retinoid chemoprevention of aerodigestive carcinogenesis....Pages 298-302
Definite radiation and concomitant Cisplatin administration in locally advanced head and neck cancer....Pages 303-306
Front Matter....Pages 177-177
Improved survival of patients with advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy....Pages 307-310
Treatment of patients with cancer of the head and neck or esophagus with carboplatin, 5-FU, Interferon-α and interleukin-2....Pages 311-314
Surgical considerations in the treatment of well-differentiated thyroid cancer....Pages 315-318
Front Matter....Pages N1-N1
Intensive chemotherapy with recombinant-human granulocyte-macrophage colony stimulating factor (r-hu-gm-csf) for small cell lung cancer (sclc): a pilot study....Pages 319-321
Sequential high-dose chemotherapy with r-metHu-G-CSF (Filgrastim) and infusion of peripheral blood progenitor cells (PBPC) in patients with small cell lung cancer (SCLC). A feasibility study....Pages 322-327
Cisplatinum and 5-Fluorouracil in small cell lung cancer....Pages 328-330
Phase I-II study of oral Etoposide and modulation of drug resistance with ketoconazole in small cell lung cancer....Pages 331-335
Angiogenesis: a novel target for Adjuvant chemotherapy in locally advanced non-small cell lung cancer....Pages 336-342
A statistical model for investigating Adjuvant chemotherapy in T1N0M0 non-small cell lung cancer....Pages 343-347
A combination chemotherapy with Ifosfamide (I), Cisplatin (P) and Etoposide (E) for advanced non-small cell lung cancer (NSCLC)....Pages 348-350
Mitomycin, Ifosfamide and Platin (MIP) in advanced and disseminated non-small cell lung cancer (NSCLC)....Pages 351-353
Phase III randomized study of Neo-Adjuvant chemotherapy surgery in non-small cell lung cancer (NSCLC) preliminary results....Pages 354-356
Vinorelbine, 5-Fluorouracil, Folinic acid and Cisplatin in non-small cell lung cancer: Vindesine for Vinorelbine?....Pages 357-361
Preoperative chemotherapy in non-small cell lung cancer (NSCLC) — A pilot study....Pages 362-365
Neo-Adjuvant Cisplatin and Etoposide for stage IIIA (clinical N2) non-small cell lung cancer....Pages 366-369
Concomitant chemoradiotherapy with Cisplatin dose escalation as palliative therapy for advanced malignancies of the chest....Pages 370-374
Concomitant chemoradiotherapy for inoperable non-small cell carcinoma of the lung: results of continuous infusion Cisplatin in 85 patients....Pages 375-376
Late results of Neo-Adjuvant chemoradiotherapy for primary inoperable non-small cell lung cancer....Pages 377-379
Front Matter....Pages 381-381
Conservative treatment of esophagus cancer concomitant chemoradiotherapy treatment. First results of a 143 patients serial....Pages 383-385
Induction chemotherapy, surgery and concomitant chemoradiotherapy for carcinoma of the esophagus....Pages 386-388
Front Matter....Pages 381-381
Superiority of combined chemoradiotherapy to radiotherapy alone in patients with esophageal cancers. An intergroup study....Pages 389-392
Neo-Adjuvant chemotherapy for advanced gastric cancer: a pilot study with angiotensin II induced drug delivery system....Pages 393-395
Combination of 5-FU, Leucovorin and Cisplatin (CDDP): an efficient low-toxic chemotherapy in advanced gastric adenocarcinoma....Pages 396-398
Adjuvant chemotherapy and radiotherapy in liver transplantation for primary hepatocellular carcinoma: a feasibility study....Pages 399-404
Intensive weekly chemotherapy for advanced gastric cancer using 5-Fluorouracil, Cisplatin, Epirubicin, 6S-Leucovorin and Granulocyte-colony stimulating factor....Pages 405-410
Neo-Adjuvant chemotherapy for inoperable gastric cancer via local and general delivery routes (FLEP Therapy)....Pages 411-413
Gastric cancer — a place for preoperative induction regional chemotherapy....Pages 414-418
α-2b-Interferon (IFN) plus chemotherapy in inoperable biliary-tract carcinoma, preliminary data....Pages 419-421
A phase II study of weekly 48 hours infusion with high-dose Fluorouracil (FU) in colorectal cancer....Pages 422-427
Phase II trial of Fluorouracil, Leucovorin and Interferon-α....Pages 428-432
Continuous simultaneous intra-arterial and intravenous therapy of liver metastases of colorectal carcinoma. Results of a prospective randomized study....Pages 433-440
D-Verapamil and Adriamycin in the treatment of advanced colorectal cancer....Pages 441-443
Perioperative multimodal treatment of locally advanced rectal cancer. Results of a pilot study....Pages 444-450
Front Matter....Pages 451-451
Neo-Adjuvant chemotherapy for advanced ovarian cancer....Pages 453-459
Hyperfractionation using weekly Cisplatin, Cyclophosphamide and Adriamycin (CAP) in advanced epithelial tumors of the ovary....Pages 460-463
Adjuvant treatment of ovarian carcinoma....Pages 464-468
Cyclophosphamide (CTX) and high-dose 4-Epidoxorubicin (EPI) in advanced ovarian cancer (OC) treatment....Pages 469-472
High-dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT) in 39 advanced ovarian cancers: long-term results....Pages 473-475
Concomitant chemotherapy and radiotherapy in the treatment of advanced cervix carcinomas....Pages 476-478
Adjuvant chemotherapies for small cell carcinoma of the uterine cervix....Pages 479-481
Front Matter....Pages 451-451
Neo-Adjuvant M-VAC (Methotrexate, Vinblastine, Doxorubicin, Cisplatin) chemotherapy for locally advanced or metastatic cervical and vaginal cancer....Pages 482-484
A phase II trial of Neo-Adjuvant chemotherapy (CT) with Ifosfamide (I), Mesna and Cisplatinum (C) in stage IIA-IIIB cervical cancer....Pages 485-487
Bleomycin, Ifosfamide and Carboplatin in advanced uterine cervix carcinoma: preliminary results....Pages 488-491
Front Matter....Pages 493-493
Surveillance in stage I non-seminomatous germ cell tumors of the testis (NSGCTT). Experience at the Instituto Nacional de Cancerología of México....Pages 495-498
Combination chemotherapy with Etoposide, Cisplatin, Bleomycin, and Cyclophosphamide for advanced metastatic non-seminomatous germ cell tumors....Pages 499-502
Extented resection after primary chemotherapy for residual malignant non-seminomatous germ-cell tumors of the mediastinum : is it worthwhile?....Pages 503-509
The prediction of treatment outcomes in non-seminomatous extragonadal germ cell tumors (NSEGCT) by using different criteria of « poor » and « good » risk....Pages 510-512
Advanced seminoma treated with chemotherapy (CT)....Pages 513-515
Concomitant 5-FU-CDDP and bifractionated split course radiation therapy for invasive bladder cancer....Pages 516-519
Neo-Adjuvant treatment for locally advanced bladder cancer : a randomized prospective clinical trial....Pages 520-522
Ultrastructural and clinical study of the urothelium after Interferon α -2b treatment....Pages 523-526
Chemo-radiotherapy in locally advanced bladder cancer: Neo-Adjuvant and definitive treatment....Pages 527-534
Interferon- α (IFN- α ) combined with 5-Fluorouracil (5-FU) is an active regimen in metastatic renal cell cancer....Pages 535-539
Comparative efficacy of hormonal therapy used alone or in combination for treatment of prostatic carcinoma....Pages 540-541
Etoposide in treatment of hormone refractory advanced carcinoma of the prostate....Pages 542-547
Sequential therapy with recombinant Interleukin-2 (rIL-2) and α -interferon (IFN) for advanced renal cell cancer (rcc) : a preliminary report....Pages 548-550
No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors....Pages 551-554
Front Matter....Pages 555-555
Initial experience with autologous transplantation of 7 days non-cryopreserved peripheral blood stem cells, mobilized with G-CSF, in rhabdomyosarcoma....Pages 557-560
High-dose chemotherapy with granulocyte colony-stimulating factor in advanced and/or metastatic soft tissue sarcomas....Pages 561-564
Treatment of osteosarcoma with Cisplatin and Doxorubicin either as Adjuvant or Neo-Adjuvant chemotherapy....Pages 565-567
Front Matter....Pages 555-555
The role of preoperative and Adjuvant chemotherapy in the treatment on non rhabdomyosarcoma soft tissue sarcoma in children and adolescents....Pages 568-572
Escalating doses of Epirubicin in combination with Ifosfamide and GM-CSF in previously untreated soft tissue sarcoma patients; a phase I–II study....Pages 573-576
Primary chemotherapy in malignant fibrous histiocytoma of bone — Updated UTMD Anderson Cancer Center Experience....Pages 577-580
Concomitant radiation-Doxorubicin administration in locally advanced and/or metastatic soft tissue sarcomas....Pages 581-583
Front Matter....Pages 585-585
Chemotherapy as a first treatment for malignant primary CNS non-Hodgkin’s lymphoma of the central nervous system (PCNSL)....Pages 587-589
Effect of six retinoids and retinoic acid catabolic inhibitor liarozole on two glioblastoma cell lines, and in-vivo experience in malignant brain tumor patients....Pages 590-598
Phase II trial with BCNU Plus α -2B-Interferon in patients with recurrent high-grade gliomas....Pages 599-603
Carboplatin combined with Carmustine and Etoposide in the treatment of glioblastoma (GBM) patients....Pages 604-606
Phase II trial of Cystemustine, a new nitrosourea, as second-line treatment of malignant gliomas....Pages 607-611
Age effect on the survival of patients with glioblastoma and anaplastic astrocytoma....Pages 612-615
Concurrent radiochemotherapy in high-grade glioma....Pages 616-619
Interferon- α -2b + fotemustine in disseminated malignant melanoma....Pages 620-622
Tamoxifen-augmented biochemotherapy (Interferon- α -2b, Tamoxifen, BCNU, CDDP, DTIC) for malignant melanoma....Pages 623-627
Front Matter....Pages 629-629
Chemofiltration for locally advanced cancer....Pages 631-634
Treatment optimization guidelines for hyperthermic antiblastic limb perfusion....Pages 635-638
5-FU + Folinic Acid (FA, Rescuvolin®) i.a., 5-FU + FA i.v., 5-FUDR i.a., or 5-FUDR i.a. + i.v. for treatment of non-resectable colorectal liver metastases ?....Pages 639-648
Hepatic arterial chemotherapy (HAI) for unresectable liver metastases from gastrointestinal cancer....Pages 649-651
The treatment of presacral recurrences of rectal cancer by the use of loco-regional pelvic chemotherapy. A discussion of these methods as a Neo-Adjuvant time in locally advanced rectal tumors....Pages 652-657
Repeated chemo-occlusion with Degradable Starch Microspheres (DSM)-Enhanced drug uptake and regional efficacy in the treatment of primary and secondary liver tumors....Pages 658-664
Antitumor efficacy of intraperitoneal hyperthermochemotherapy combined with aggressive surgery for patients with advanced gastric cancer....Pages 665-668
Front Matter....Pages 629-629
Intraperitoneal hyperthermic chemoperfusion in patients with peritoneal carcinomatosis and malignant ascites....Pages 669-671
Intra-aortic infusion chemotherapy in advanced penile carcinoma....Pages 672-674
Front Matter....Pages 675-675
The influence of both surgery and Adjuvant chemotherapy on breast cancer women quality of life....Pages 677-680
Psychological side effects induced by Interleukin-2/ α -Interferon: clinical observations, biological correlations....Pages 681-690
Quality of life in advanced colorectal cancer....Pages 691-694
Advance directives in the intensive care unit of a tertiary cancer center....Pages 695-698
Do cancer related pain problems exist in France ?....Pages 699-701
Intravenous granisetron-simple, safe and effective single-dose. Administration for control of chemotherapy induced nausea and vomiting....Pages 702-704
Control of refractory nausea and vomiting with adjuvant propofol during cancer chemotherapy....Pages 705-706
Liposomal Daunorubicin treatment increases quality of life in HIV-associated Kaposi’s Sarcoma....Pages 707-709
Front Matter....Pages 711-711
Comparison of 12 multidrug-resistance modulating agents in a model of doxorubicin-resistant rat glioblastoma cells in vitro....Pages 713-719
Differential formation, repair and tolerance of Cisplatin-induced DNA damage in two human small cell lung carcinoma cell lines....Pages 720-722
Identification of a distinctive multiple drug resistance phenotype in tumour cells following in vitro exposure to X-irradiation....Pages 723-725
Functional activity of P-glycoprotein localized in subcellular structures and reversal of multidrug resistance (MDR)....Pages 726-729
New strategy for the production of monoclonal antibodies to external portion of the P-glycoprotein....Pages 730-735
Myeloperoxidase is involved in Vincristine resistance in human myeloblastic leukemia....Pages 736-739
A new multidrug resistance modulating agent S 9788: preliminary report of the phase clinical trial in combination with Vincristine....Pages 740-744
Effect of Pentoxifylline, ethacrynic acid and O 6 -benzyl-guanine as resistance modifiers to alkylating agents in haematological malignancies....Pages 745-748
Structural alterations of human topoisomerase IIα responsible for drug-resistance, DNA-binding and nuclear localization....Pages 749-756
Measurement of human tumor pharmacokinetics in vivo noninvasively by 19-F magnetic resonance spectroscopy predicts clinical 5-FU sensitivity and resistance....Pages 757-758
Front Matter....Pages 711-711
Immunoregulation by tumor necrosis factor α (TNF): an opportunity for therapeutic intervention ?....Pages 759-764
Tumor necrosis factor alpha: its relationship with clinical data....Pages 765-769
The antiproliferative effect of lymphoblastoid α interferon and its ability to re-induce or amplify major histocompatibility complex antigen expression on human renal carcinoma cells in culture....Pages 770-773
Is there any predictive factor of the clinical response to IL-2 therapy in metastatic malignant melanoma ?....Pages 774-778
How IL-2 can affect melanoma cells....Pages 779-784
Potentiation of 5-Fluorouracil-[6RS]leucovorin cytotoxicity by recombinant human Interferon- α 2A in colon carcinoma cells....Pages 785-788
Evidence for a role of immunosuppression in the pathogenesis of small cell lung cancer....Pages 789-793
p53 expression in human soft tissue sarcomas. Correlation with biological aggressiveness....Pages 794-797
Synergistic cytotoxicity as an endpoint for the development of rational chemotherapeutic. Drug combinations....Pages 798-803
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications....Pages 804-808
Clinical studies of CPT-11 in Japan....Pages 809-812
Evaluation of CPT-11 against human xenografts of colon adenocarcinoma and childhood sarcomas....Pages 813-816
Microencapsulation, Tamoxifen analogues, and in vivo microscopy for tumor targeting....Pages 817-819
A new generation of Doxorubicin-loaded liposomes with improved localization in tumors: preclinical and clinical studies....Pages 820-822
Degradable starch microspheres increase the cytostatic effect of the bioreductive drug RSU-1069 (aziridine 2-nitroimidazole) at arterial administration in rats with a liver carcinoma....Pages 823-825
Therapeutic use of polyspecific mab-labelled liposomes as carriers for radioisotopes and drugs....Pages 826-832
An in vitro model for neutrophil-mediated damage to tumour vasculature: effects of a novel anti-cancer agent....Pages 833-837
Stimulation of tumor growth in vitro and in vivo by Suramin in an experimental model....Pages 838-842
Phase I-II trial of Seraspenide (AcSDKP): a supressor of myelopoiesis protects against chemotherapy myelotoxicity (version 10 february 1993)....Pages 843-849
A review on the use of sheep epidermal squamous cell carcinoma to evaluate intra-arterial infusion chemotherapy....Pages 850-854
Front Matter....Pages 711-711
Cellular and pharmacokinetic factors which influence genotoxicity of topoisomerase II inhibiting drugs in human leukemia cells....Pages 855-860
Clinical application of gene transfer in oncology: preliminary results of a French study....Pages 861-864
Effects of Vitamin-A on the oestrogen dependant breast carcinoma cell line ZR75-1....Pages 865-870
Measurement of the early level of mdr1 gene expression is a predictive marker of tumour response in breast cancer patients treated by Neo-Adjuvant chemotherapy....Pages 871-874
Hematologic effects of recombinant human Interleukin-6 (rhIL-6) in sarcoma patients receiving maid chemotherapy: phase I trial....Pages 875-879
Role of G-CSF and GM-CSF in the treatment of febrile neutropenia induced by chemotherapy ; preliminary results of a randomized trial....Pages 880-884
First line chemotherapy for patients with multiple myeloma with vad regimen followed by consolidation with high-dose chemoradiotherapy with peripheral stem cells autograft (PSCA): the experience of IGR center....Pages 885-888
Back Matter....Pages 889-901